Compare Inovio Pharmaceuticals Inc (INO) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs iShares MBS ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while iShares MBS ETF trades at $93.39. The key difference: iShares MBS ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | MBB | |
|---|---|---|
Market Cap | $89.27M | — |
Sector | Health | — |
52-Week High | $2.87 | $96.91 |
52-Week Low | $1.05 | $92.92 |
Enterprise Value | $60.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
MBB (iShares MBS ETF) trades at $93.41, down 0.39% on the day, with a bearish technical signal from moving averages and key indicators like ADX showing strong sell signals. The ETF has maintained consistent dividend payments, with recent distributions of $0.33-$0.34 per share. Institutional activity shows mixed sentiment with Comerica Bank reducing its position while Concurrent Investment Advisors and Aureum Wealth Management increased their stakes significantly.
The ETF faces headwinds from the bearish technical setup and mortgage market volatility, though consistent dividend payments provide income stability. Key risks include interest rate sensitivity and MBS market liquidity, while institutional accumulation suggests some long-term confidence in the asset class despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
